HomeNewsMigraine Prevention Therapy Emgality Will get FDA Approval
Posted in News on 1st October 2018
Emgality is a calcitonin-gene related peptide antagonist

Emgality is a calcitonin-gene related peptide antagonist

The Food and Drug Administration (FDA) has approved Emgality (galcanezumab-gnlm; Lilly), a once-monthly preventive treatment for adult patients with migraine. Galcanezumab-gnlm is a humanized IgG4 monoclonal antibody specific for calcitonin-gene related peptide (CGRP) ligand.

The approval was based on data from 3 randomized, double-blind, placebo-controlled trials (EVOLVE-1, EVOLVE-2, REGAIN) in patients with either episodic or chronic migraine.  Results from the trials showed that treatment with Emgality was associated with significantly greater reduction in monthly migraine headache days compared with placebo. With regard to safety, the most common adverse reactions in Emgality clinical trials were injection site reactions.

Emgality will be supplied in 120mg/mL single-dose prefilled pens as well as prefilled syringes. The treatment is intended for patient self-administration via subcutaneous injection. Prior to use, clinicians should train patients and caregivers on how to prepare and administer Emgality.

Emgality is expected to be available shortly, according to Lilly. The list price is $ 575 per month, or $ 6,900 annually. For patients with commercial insurance, Lilly is providing a patient support program that will cover the cost of Emgality for up to 12 months.

Related Post for New antibody can scale back swelling assaults in sufferers with hereditary angioedema

Botulinum toxin injections present promise to suppress postoperative atrial fibrillation
FDA: Critical Aspect Impact of AML Drug Not Being Acknowledged
New ointment for treating brown recluse spider bites is examined on people
FDA: MS Drug Linked to Circumstances of Stroke, Blood Vessel Wall Tears
New antibody can scale back swelling assaults in sufferers with hereditary angioedema